Literature DB >> 25972245

Structural and functional consequences of succinate dehydrogenase subunit B mutations.

E Kim1, E M Rath2, V H M Tsang3, A P Duff2, B G Robinson3, W B Church2, D E Benn2, T Dwight2, R J Clifton-Bligh3.   

Abstract

Mitochondrial dysfunction, due to mutations of the gene encoding succinate dehydrogenase (SDH), has been implicated in the development of adrenal phaeochromocytomas, sympathetic and parasympathetic paragangliomas, renal cell carcinomas, gastrointestinal stromal tumours and more recently pituitary tumours. Underlying mechanisms behind germline SDH subunit B (SDHB) mutations and their associated risk of disease are not clear. To investigate genotype-phenotype correlation of SDH subunit B (SDHB) variants, a homology model for human SDH was developed from a crystallographic structure. SDHB mutations were mapped, and biochemical effects of these mutations were predicted in silico. Results of structural modelling indicated that many mutations within SDHB are predicted to cause either failure of functional SDHB expression (p.Arg27*, p.Arg90*, c.88delC and c.311delAinsGG), or disruption of the electron path (p.Cys101Tyr, p.Pro197Arg and p.Arg242His). GFP-tagged WT SDHB and mutant SDHB constructs were transfected (HEK293) to determine biological outcomes of these mutants in vitro. According to in silico predictions, specific SDHB mutations resulted in impaired mitochondrial localisation and/or SDH enzymatic activity. These results indicated strong genotype-functional correlation for SDHB variants. This study reveals new insights into the effects of SDHB mutations and the power of structural modelling in predicting biological consequences. We predict that our functional assessment of SDHB mutations will serve to better define specific consequences for SDH activity as well as to provide a much needed assay to distinguish pathogenic mutations from benign variants.
© 2015 Society for Endocrinology.

Entities:  

Keywords:  SDHB; functional consequences; paraganglioma; phaeochromocytoma; succinate dehydrogenase

Mesh:

Substances:

Year:  2015        PMID: 25972245     DOI: 10.1530/ERC-15-0099

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  9 in total

1.  Implications of SDHB genetic testing in patients with sporadic pheochromocytoma.

Authors:  Aurelie Maignan; Carole Guerin; Valentin Julliard; Nunzia-Cinzia Paladino; Edward Kim; Philippe Roche; Fréderic Castinetti; Wassim Essamet; Julien Mancini; Alessio Imperiale; Roderick Clifton-Bligh; Pauline Romanet; Anne Barlier; Karel Pacak; Fréderic Sebag; David Taïeb
Journal:  Langenbecks Arch Surg       Date:  2017-02-22       Impact factor: 3.445

2.  LASS5 Interacts with SDHB and Synergistically Represses p53 and p21 Activity.

Authors:  Z Jiang; F Li; Y Wan; Z Han; W Yuan; L Cao; Y Deng; X Peng; F Chen; X Fan; X Liu; G Dai; Y Wang; Q Zeng; Y Shi; Z Zhou; Y Chen; W Xu; S Luo; S Chen; X Ye; X Mo; X Wu; Y Li
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

Review 3.  Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry.

Authors:  C Christofer Juhlin
Journal:  Endocr Pathol       Date:  2021-03-25       Impact factor: 3.943

4.  Utility of the succinate: Fumarate ratio for assessing SDH dysfunction in different tumor types.

Authors:  Edward Kim; Michael Jp Wright; Loretta Sioson; Talia Novos; Anthony J Gill; Diana E Benn; Christopher White; Trisha Dwight; Roderick J Clifton-Bligh
Journal:  Mol Genet Metab Rep       Date:  2016-12-30

5.  Analysis of SDHAF3 in familial and sporadic pheochromocytoma and paraganglioma.

Authors:  Trisha Dwight; Un Na; Edward Kim; Ying Zhu; Anne Louise Richardson; Bruce G Robinson; Katherine M Tucker; Anthony J Gill; Diana E Benn; Roderick J Clifton-Bligh; Dennis R Winge
Journal:  BMC Cancer       Date:  2017-07-24       Impact factor: 4.430

6.  SDHA related tumorigenesis: a new case series and literature review for variant interpretation and pathogenicity.

Authors:  Ruth T Casey; David B Ascher; Eleanor Rattenberry; Louise Izatt; Katrina A Andrews; Helen L Simpson; Benjamen Challis; Soo-Mi Park; Venkata R Bulusu; Fiona Lalloo; Douglas E V Pires; Hannah West; Graeme R Clark; Philip S Smith; James Whitworth; Thomas G Papathomas; Phillipe Taniere; Rosina Savisaar; Laurence D Hurst; Emma R Woodward; Eamonn R Maher
Journal:  Mol Genet Genomic Med       Date:  2017-03-02       Impact factor: 2.183

Review 7.  Succinate dehydrogenase and MYC-associated factor X mutations in pituitary neuroendocrine tumours.

Authors:  Paul Benjamin Loughrey; Federico Roncaroli; Estelle Healy; Philip Weir; Madhu Basetti; Ruth T Casey; Steven J Hunter; Márta Korbonits
Journal:  Endocr Relat Cancer       Date:  2022-09-02       Impact factor: 5.900

8.  One genotype, many phenotypes: SDHB p.R90X mutation-associated paragangliomas.

Authors:  Ali S Alzahrani; Meshael Alswailem; Yosra Moria; Ayman Aldeheshi; Hindi Al-Hindi
Journal:  Endocrine       Date:  2020-08-17       Impact factor: 3.633

9.  High-frequency actionable pathogenic exome variants in an average-risk cohort.

Authors:  Shannon Rego; Orit Dagan-Rosenfeld; Wenyu Zhou; M Reza Sailani; Patricia Limcaoco; Elizabeth Colbert; Monika Avina; Jessica Wheeler; Colleen Craig; Denis Salins; Hannes L Röst; Jessilyn Dunn; Tracey McLaughlin; Lars M Steinmetz; Jonathan A Bernstein; Michael P Snyder
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-12-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.